New Management of BioStem Technologies (BSEM) Announces Name and
Symbol Change To Be In Effect Today. BSEM Also Moves Forward To
Complete An Interactive Webpage, And Will Be Attending the 22nd
Annual World Congress On Anti-Aging Medicine Dec 11-13, 2014.
Oakland Park, FL – Biostem Technologies, Inc. (BSEM), is pleased
to announce the Financial Industry Regulatory Agency (FINRA) has
approved a name and symbol change from Caribbean International
Holdings, Inc. to Biostem Technologies, Inc. (BSEM) effective
today. The new management believes this name will reflect Biostem
Technologies, Inc.’s new focus.
Biostem Technologies, Inc. is an emerging Regenerative Medicine
company with a vast amount of scientific and clinical knowledge;
this knowledge allows (BSEM) to effectively treat patients, explore
cutting edge protocols and develop breakthrough treatments. Biostem
Technologies, Inc. is focused on evolving the emerging Stem Cell
industry with innovative protocols for treatment in an array of
rare and common degenerative diseases.
Biostem Technologies, Inc. is also excited to announce its
progress on its new interactive website currently in production.
This web page will include; but not limited to, a look at our
facilities, doctors, and informative articles on stem cell therapy
and regenerative medicine. In addition to the website Biostem
Technologies, Inc. has launched a new Twitter page (@biostemtech)
to help keep the public informed of upcoming news and events.
Biostem Technologies, Inc. management along with Dr. Rafael
Gonzalez, will also be attending the 22nd Annual World Congress on
Anti-Aging Medicine. The A4M conference is taking place in Las
Vegas, NV on December 11-13th,. Dr. Gonzalez has become a key
opinion leader in the biomedical industry and has expansive
knowledge on the behavior and expansion of stem cells and stem cell
cryopreservation. His research includes stem cell applications for
multiple diseases, degenerative disorders and research on the
behavior of stem cell cultures and cell biology from several
development stages.
About Cryopreservation & Culture Expansion of Stem
Cells:
Mesenchymal stem cells (MSCs) may be isolated from tissues such
as adipose, bone marrow, umbilical cord tissue and blood. Following
tissue processing, you will have the option of using your mixed
cell product, such as stromal vascular fraction or purification of
MSCs by expansion in culture. In 2006, there was a set of
guidelines defining MSCs. One of the main characteristics is the
ability to adhere to plastic. For cells to adhere to plastic, they
require culture expanding MSCs and eventual cryopreservation. We
will discuss methods of culture expansion and cryopreservation of
MSCs. We will overview the use of the reagents necessary to start
and expand MSCs. In addition, we will analyze methods of
mesenchymal stem cell culture expansion and their implications in
patient treatment. We will also discuss the importance and
logistics of the cryopreservation process for your expanded
MSCs.
About The American Academy of Anti-Aging Medicine (A4M):
The American Academy of Anti-Aging Medicine (A4M) is a US
federally registered 501(c) 3 non-profit organization comprised of
over 26,000 members including: physicians, health practitioners,
scientists, government officials, and members of the general
public, representing over 110 nations.
The A4M is dedicated to the advancement of technology to detect,
prevent, and treat aging related diseases and to promote research
into methods to retard and optimize the human aging process. The
A4M is also dedicated to educating physicians, scientist, and
members of the public on biomedical sciences, breaking
technologies, and anti-aging issues.
About Biostem Technologies, Inc. (BSEM):
Biostem Technologies, Inc. is a holding company for Regenerative
Bio Science, Inc. ("RBSI"). The Company subsidiary RBSI is focused
on helping individuals protect and ensure their future quality of
life through Adult and/or Cord Blood Stem Cell Incubation and the
practice of regenerative medicine in the United States and the
Dominican Republic. RBSI's mission is not only to allow patients to
store their Stem Cells for future use, but also perform patient
funded stem cell therapies from sports injuries to degenerative
diseases such as MS, Arthritis, Degenerative Heart Diseases,
Diabetes and a host of experimental therapies in the brain trauma
disease sector including CTE. The goal is to become a global leader
in establishing protocols that can be patented and utilized to heal
patients around the world.
Stem cells work as the repairmen of the body by replenishing and
regenerating damaged tissues and cells. Certain conditions have
shown marked improvement when treated with stem cells taken from
the patient's own body as well as Cord Blood stem cells.
Regenerative Bioscience is becoming part of a revolution in
healthcare using stem cells.
Forward-Looking Statements Except for statements of historical
fact, the matters discussed in this press release are forward
looking and made pursuant to the Safe Harbor provisions of the
Private Securities Litigation Reform Act of 1995. "Forward-looking
statements" describe future expectations, plans, results, or
strategies and are generally preceded by words such as "future,"
"plan" or "planned," "expects," or "projected." These
forward-looking statements reflect numerous assumptions and involve
a variety of risks and uncertainties, many of which are beyond the
company's control that may cause actual results to differ
materially from stated expectations. These risk factors include,
among others, limited operating history, difficulty in developing,
exploiting and protecting proprietary technologies, intense
competition and additional risks factors as discussed in reports
filed by the company with the Securities and
Exchange Commission, which are available on at http://www.sec.gov.
Contact:
Biostem Technologies, Inc.
Phone: 954-380-8342
Website: http://www.biostemtech.com
Email: info@biostemtech.com
Twitter: @Biostemtech